NEW YORK, May 5, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Puma Biotechnology, Inc. ("Puma Biotechnology" or the "Company") (NASDAQ: PBYI)
The investigation focuses on whether the Company and its executives violated federal securities laws. Specifically, on May 5, 2017, the Company disclosed the resignation of the Company's Senior Vice President, citing "health reasons." Dr. Charnas's resignation will be effective as of May 15, 2017, nine days before the U.S. Food and Drug Administration's scheduled review of Puma's breast cancer drug neratinib on May 24, 2017.
After the announcement, Puma Biotechnology's share price fell from $36.55 per share on May 4, 2017 to $29.85 during intraday trading on May 5, 2017—a $6.70 or a 18.08% drop.
If you invested in Puma Biotechnology stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/PBYI. There is no cost or obligation to you.
You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to email@example.com.
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Telephone: (877) 247-4292 or (212) 983-9330
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/puma-biotechnology-investor-alert-faruqi--faruqi-llp-encourages-investors-who-suffered-losses-exceeding-100000-investing-in-puma-biotechnology-inc-to-contact-the-firm-300452401.html
SOURCE Faruqi & Faruqi, LLP